Find A Physician
Return to New Hope for Patients Suffering From Chronic Depression Overview
More on New Hope for Patients Suffering From Chronic Depression
Hospital News
Return to New Hope for Patients Suffering From Chronic Depression Overview
More on New Hope for Patients Suffering From Chronic Depression
- Weill Cornell Institute for Geriatric Psychiatry Awarded $10 Million Grant
- Care Management Reduces Depression and Suicidal Thoughts in Older Primary Care Patients
- New Research Under Way to Study Treatment for Older Adults With Bipolar Disorder
- White House Awards NewYork-Presbyterian/Weill Cornell's Dr. Francis Lee the Highest Honor for Early Career Scientists
- Preventing Suicide Among College Students
- Research Pioneer in the Developmental Origins of Psychiatric Illness is Awarded the Mortimer D. Sackler, M.D., Prize for Distinguished Achievement in Developmental Psychobiology
- Toward Our Understanding of Tourette Syndrome
- Major Geriatric Bipolar Disorder Study Now Under Way
- The New York Community Trust's DeWitt Wallace Fund Gives Nearly $70 Million to Advance Psychiatry at NewYork-Presbyterian/Weill Cornell
- Bereaved Children of 9/11 Victims Suffered High Rates of Psychiatric Illness
- Scientific Evidence Points to Male Biological Clock
- NewYork-Presbyterian/Weill Cornell and Johns Hopkins Study Finds Anxiety and Depression Lead to Lost Performance, Lost Profit in the Workplace
- Nerve-Stimulation Therapy for Patients with Treatment-Resistant Depression Now Available in New York
- Innovative Mental Health Care in a Primary Care Setting Available Through NewYork-Presbyterian
- Noted Weill Cornell Psychiatrist Awarded Grant To Study Effects of Parental Suicide
- Weill Cornell Institute and Westchester County Share $1.5 Million Grant on Depression in Older Adults
- Omega-3 Fatty Acids: Good For the Heart, and (Maybe) Good for the Brain
- Cornell Study of Geriatric Depression Opens Door for Further Research on Treatment and Prevention
- Coping With Chronic Cancer Pain
- Children with Psychiatric Emergencies Have Unique Issues That Require New Strategies for Treatment
- Weill Cornell Psychiatrists Receive Federal Grant To Study Effects of Stress on Children Who Lost Parents on September 11
- Columbia University, NewYork-Presbyterian Hospital and New York City Police Foundation Provide Free, Confidential Counseling To NYPD
Research and Clinical Trials
Return to New Hope for Patients Suffering From Chronic Depression Overview
More on New Hope for Patients Suffering From Chronic Depression
Health Library
Return to New Hope for Patients Suffering From Chronic Depression Overview
More on New Hope for Patients Suffering From Chronic Depression
Clinical Services
Return to New Hope for Patients Suffering From Chronic Depression Overview
More on New Hope for Patients Suffering From Chronic Depression
New Hope for Patients Suffering From Chronic Depression
NY Weill Cornell Participates in Landmark Chronic Depression Study That Shows Drug-Psychotherapy Combination To Be Effective
NEW YORK (May 18, 1999)
A new combination of drug treatment and psychotherapy is much more effective than either medication or therapy alone for treating chronic depression, according to preliminary results presented today at the 1999 annual meeting of the American Psychiatric Association.
The study was conducted jointly by researchers from 12 academic medical centers nationwide. James H. Kocsis, M.D., Professor of Psychiatry and John C. Markowitz, M.D., Associate Professor of Clinical Psychiatry, are the principal investigators of the study at New York Weill Cornell Center of New York Presbyterian Hospital.
The combination treatment, involving the drug nefazodone and a form of psychotherapy developed specifically to treat chronic depression, also produced the highest response and remission rates for any reported study of chronic depression.
The findings come from the Serzone Chronic Depression Study, the first major study of medication alone, psychotherapy alone, and the combination of both in patients with chronic depression. Nefazodone, prescribed under the brand name Serzone™, is used to treat depression and is effective for reducing relapse.
Results from the acute phase—the first 12 weeks—of the 80-week study of 681 patients depressed for at least two years show that a combination of nefazodone and psychotherapy produces an 85 percent response rate. The drug alone leads to a 55 percent rate of response, similar to 52 percent response rate for psychotherapy.
"This study should put to rest the widespread belief that chronic depression is resistant to drug treatments and psychotherapy," said Dr. Kocsis. "It should offer great hope for recovery for patients suffering from chronic depression because this study demonstrates that an extremely high proportion of patients can be effectively treated with Serzone and psychotherapy specifically developed to treat chronic depression."
The research includes a 16-week continuation trial for patients who respond positively to nefazodone or to the combination treatment in the acute phase followed by a 52-week maintenance treatment to evaluate the drug versus a placebo.
About 14 million Americans suffer from chronic forms of depression, marked by disabling psychological and social problems. These individuals are often misdiagnosed as having character and personality disorders.
"The next step is to translate the acute phase findings into appropriate treatment guidelines for initial management of chronic depression," commented Dr. Kocsis. "We have a very stong evidence that a structured, cognitive-based therapy is very effective. We hope this will lead to more chronically depressed people receiving these treatments so response rates will be higher."
